Stem cell educator therapy may help fight diabetes

Stem cell educator therapy may help fight diabetes

(HealthDay)—Stem cell educator therapy may provide long term benefits in type 1 and type 2 diabetes, according to a study published online July 7 in Stem Cells Translational Medicine.

Yong Zhao, M.D., Ph.D., an associate scientist at the Hackensack University Medical Center in New Jersey, and colleagues looked at four years of data on nine type 1 in China. Two individuals with type 1 who received a stem cell educator treatment shortly after diagnosis (five and eight months later) still had normal C-peptide production and didn't need insulin four years after a single treatment. Another type 1 patient had had the disease for four years when she received treatment. She still had improvements in her C-peptide levels, but wasn't considered in remission. The remaining six with type 1 saw decreases in their C-peptide levels over time.

The researchers also looked at six patients with severe, long-standing (15 to 24 years) type 2 diabetes. They found that one treatment helped four patients achieve normal C-peptide levels and maintain them over the four-year follow-up. "For the four type 2 patients, their C-peptide is very stable after one treatment," Zhao told HealthDay.

"Stem cell educator therapy is a safe approach" with long-term effectiveness, said Zhao. In addition to helping people with diabetes, Zhao said the could help with other autoimmune diseases, possibly including alopecia areata, lupus, Hashimoto's thyroiditis, and Sjogren's syndrome.


Explore further

'Educating' patients' immune cells may help combat diabetes

More information: Abstract
Full Text

Copyright © 2017 HealthDay. All rights reserved.

Citation: Stem cell educator therapy may help fight diabetes (2017, July 17) retrieved 16 September 2019 from https://medicalxpress.com/news/2017-07-stem-cell-therapy-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
85 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more